沃特世公司（WAT）周一宣布，将以价值175亿美元的股票和现金交易方式，合并碧迪医疗（BDX）的生物科学与诊断解决方案业务。受此消息影响，WAT股价当日收盘暴跌13.8%，至少两家券商迅速下调了其目标价。市场观点出现显著分歧：Leerink Partners（评级"优于大盘"）指出，投资者或从交易中找到安慰，因沃特世CEO Udit Batra曾成功操盘默克集团-西格玛奥德里奇并购案；Jefferies（评级"买入"，目标价435美元）则预计短期内争论将围绕协同效应和增长潜力展开，噪音不断。然而，Morningstar（公平价值330美元）持谨慎态度，警告沃特世可能支付过高溢价，即使考虑激进协同目标，碧迪医疗的业务质量也逊于沃特世的传统领域。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.